Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors
(NASDAQ:ONCY) Data continue to demonstrate a favorable safety profile for pelareorep across multiple indications and in combination with multiple treatments Updated clinical data now account for over 300 gastrointestinal cancer patients, including patients from the GOBLET study, demonstrating...
Related Questions
How will the updated safety data for pelareorep influence Oncolytics' short‑term stock price and analyst earnings estimates?
What does the expanded safety profile across >300 GI cancer patients mean for pelareorep’s competitive positioning and potential regulatory approval timeline compared to rival therapies?
When is the next significant data read‑out or milestone (e.g., efficacy results from the GOBLET study) that could further impact the company’s market valuation?